BioSpace News Archive

How serious are you about your career development? It could be a new job, promotion, or finally aligning yourself with the organization you’ve been dreaming about for years. Most professionals will talk a lot about things they claim to want, but not actually do anything about it.

The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.

There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.

Swiss-based Ava markets the Ava bracelet, what it calls a cycle-tracking sensor bracelet. It is being sold as a way to track a woman’s fertile period, although the company suggests it plans to see if it can be used as a type of birth control.

Genomic Health, Inc. announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25.

Merck announced results from KEYNOTE-042, a pivotal, Phase 3 study evaluating KEYTRUDA

Forty Seven, Inc. announced proof-of-concept data from two separate clinical trials of 5F9: an ongoing Phase 1b/2 trial evaluating 5F9 in combination with rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL) and a Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) trial in patients with advanced solid tumors.

IM HealthScience® (IMH) announced a high-quality and replicated nationwide survey conducted among a representative and projectible sample of U.S. gastroenterologists, which revealed Fiber Choice® as the #1-recommended chewable prebiotic fiber brand.

Merck announced that the investigational, targeted therapy tepotinib* has shown clinical activity in an ongoing Phase II study of patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Data from the VISION trial will be presented during the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago, June 1-5, 2018.

Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW)